The briefing
Frank McCormick outlined the rationale for pairing KRAS inhibitors with PI3K pathway agents and immune checkpoint inhibitors to improve durability of response. The discussion centers on strategies to overcome resistance and enhance clinical outcomes.
Original headline
Combining KRAS Inhibitors With PI3K and Checkpoint Blockade to Improve Response Durability